Dyne Therapeutics (DYN) Common Equity (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Common Equity of $702.2 million for Q2 2026, up 22.87% year-over-year from $571.4 million in Q2 2025, and down 18.83% quarter-over-quarter from $865.1 million in Q1 2026.
Dyne Therapeutics (DYN) Common Equity (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Common Equity for 8 consecutive years, with $702.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity rose 22.87% year-over-year to $702.2 million; the TTM figure through Jun 2026 stood at $702.2 million (up 22.87% YoY), while the FY2025 annual figure was $972.1 million, up 54.35% from the prior year.
- Common Equity slipped to $702.2 million in Q2 2026 per DYN's latest filing, from $865.1 million in the prior quarter.
- Across five years, Common Equity topped out at $972.1 million in Q4 2025 and bottomed at $91.3 million in Q4 2023.
- Historically, Common Equity has averaged $493.2 million across 5 years, with a median of $524.8 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity slumped 63.83% — and 2024, when it jumped 589.92%.
- Dyne Therapeutics' Common Equity stood at $252.4 million in 2022, then plunged by 63.83% to $91.3 million in 2023, then surged by 589.92% to $629.8 million in 2024, then jumped by 54.35% to $972.1 million in 2025, then declined by 27.77% to $702.2 million in 2026.
- Business Quant data shows DYN's Common Equity at $702.2 million in Q2 2026, $865.1 million in Q1 2026, and $972.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 702.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 702.15 Mn |
| Mar 31, 2026 | 865.06 Mn |
| Dec 31, 2025 | 972.13 Mn |
| Sep 30, 2025 | 691.78 Mn |
| Jun 30, 2025 | 571.45 Mn |
| Mar 31, 2025 | 668.97 Mn |
| Dec 31, 2024 | 629.84 Mn |
| Sep 30, 2024 | 705.54 Mn |
| Jun 30, 2024 | 775.19 Mn |
| Mar 31, 2024 | 478.06 Mn |
| Dec 31, 2023 | 91.29 Mn |
| Sep 30, 2023 | 152.04 Mn |
| Jun 30, 2023 | 206.88 Mn |
| Mar 31, 2023 | 241.94 Mn |
| Dec 31, 2022 | 252.36 Mn |
| Sep 30, 2022 | 249.74 Mn |
| Jun 30, 2022 | 287.06 Mn |
| Mar 31, 2022 | 336.46 Mn |
| Dec 31, 2021 | 368.20 Mn |
| Sep 30, 2021 | 414.12 Mn |